The need for new medicines for previously untreatable diseases creates new challenges for drug development. When a new lead is generated, small amounts of preclinical material are needed and produced—at any cost—to demonstrate a first proof of concept. In subsequent development phases, however, the pharmaceutical company must quickly develop an acceptable and scalable synthesis of complex new drug candidates to meet accelerating timelines and rapidly move the molecule through clinical development.
To view the webinar and learn the many pieces to the development puzzle that need to be put together when taking a new chemical entity to market, please complete the short form to the right.